FDA OKs Esketamine Nasal Spray Monotherapy for Depression

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.
Medscape Medical News